Other languages BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
25.47 ^USD	+2.37%		+1.60%	-36.91%

04-07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
03-20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	04-07
BridgeBio Pharma Prices $250 Million Stock Offering	03-06
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	03-05
BridgeBio Pharma Commences $250 Million Share Offering	03-04
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	03-04
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	03-04
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	02-22
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22
KKR to acquire a stake in health tech firm Cotiviti	02-14
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	02-07
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	02-07
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy	02-05
AstraZeneca Says Phase 3 Trial of Acoramidis in Japan Well-Tolerated; Shows Consistency With Global Trial	02-02
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	02-02
AstraZeneca : essai positif dans l'amylose cardiaque	02-02
AstraZeneca celebrates latest successful trial of acoramidis in Japan	02-02
AstraZeneca's Rare Heart Disease Drug Improves Survival in Japanese Late-stage Study	02-02
Invitae Collaborates With BridgeBio Pharma for Rare Disease Therapeutics	01-30
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics	01-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Other languages

Filters